Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of generic azilsartan medoxomil 80 mg vs reference in healthy Thai adults under fasting
TCTR20260513002Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan medoxomil in hypertension (HTN) (2 arms), sponsored by Bio-innova. Primary endpoint: Primary pharmacokinetic bioequivalence endpoints. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
azilsartan medoxomil
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on TCTR20260513002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260513002.